PATENT CLAIM ANALYSIS

Application Number: 15766799
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "211100"]

Abstract:
Inhibitors of Wnt signaling pathway with structures of Formula I are disclosed, together with their pharmaceutical salts. Applications of compounds of Formula I in inhibiting or modulating the Wnt signaling pathway are also disclosed. Compounds of Formula I can treat disorders caused by aberrant activation of the Wnt signaling pathway.

Claim (Index 16):
The method of  claim 15 , wherein the disorder is a cell proliferative disorder selected from the group consisting of systemic sclerosis, skin fibrosis, idiopathic pulmonary fibrosis, renal fibrosis, liver fibrosis, drug-induced fibrosis, radiation-induced fibrosis, colorectal cancer, breast cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, pancreatic cancer, leukemia, lymphoma, neuroblastoma, retinoblastoma, sarcoma, osteosarcoma, chondosarcoma, Ewing's sarcoma, rhabdomysarcoma, brain tumor, Wilms' tumor, basal cell carcinoma, melanoma, head and neck cancer, cervical cancer and prostate cancer.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 91.0
- Lexical Diversity: 1.63636
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15620761', '15923668', '15501233', '15326262', '14342656']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8097916276049488
- 35 USC 102 Novelty (BERT): 0.5407696754238044
- Combined Prediction Score: 0.7828894323868344
- Mean Citation Score: 372.209424
- Max Citation Score: 379.16312
- Similarity Product: 227.43767495142936

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test